Furthermore, elevated baseline TNF expression in persons with MS was associated with a higher probability of developing EDA and an increased risk of disability progression over a two-year follow-up in ocrelizumab-treated patients in both RRMS and PPMS. This evidence concerns the gene TNF and myeloid sarcoma.